Vestmark Advisory Solutions Inc. Purchases Shares of 472,256 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Vestmark Advisory Solutions Inc. bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 472,256 shares of the company’s stock, valued at approximately $4,656,000. Vestmark Advisory Solutions Inc. owned approximately 0.22% of Recursion Pharmaceuticals as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in RXRX. SG Americas Securities LLC raised its position in shares of Recursion Pharmaceuticals by 21.2% during the 3rd quarter. SG Americas Securities LLC now owns 38,927 shares of the company’s stock worth $298,000 after acquiring an additional 6,818 shares in the last quarter. Commonwealth Equity Services LLC raised its position in shares of Recursion Pharmaceuticals by 35.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 21,185 shares of the company’s stock worth $162,000 after acquiring an additional 5,550 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in Recursion Pharmaceuticals during the 3rd quarter worth approximately $458,000. Raymond James & Associates purchased a new position in Recursion Pharmaceuticals during the 3rd quarter worth approximately $529,000. Finally, Independent Advisor Alliance purchased a new position in Recursion Pharmaceuticals during the 3rd quarter worth approximately $96,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Insider Activity at Recursion Pharmaceuticals

In related news, COO Tina Marriott sold 8,000 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $14.89, for a total value of $119,120.00. Following the completion of the transaction, the chief operating officer now directly owns 639,982 shares in the company, valued at $9,529,331.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Tina Marriott sold 8,000 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $14.89, for a total value of $119,120.00. Following the completion of the transaction, the chief operating officer now directly owns 639,982 shares in the company, valued at $9,529,331.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Secora sold 23,124 shares of the business’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $7.58, for a total value of $175,279.92. Following the sale, the chief financial officer now directly owns 1,231,055 shares of the company’s stock, valued at approximately $9,331,396.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 412,665 shares of company stock worth $4,036,978. 19.96% of the stock is currently owned by insiders.

Recursion Pharmaceuticals Stock Performance

RXRX stock traded up $0.05 during midday trading on Friday, hitting $8.84. 3,982,474 shares of the stock were exchanged, compared to its average volume of 4,073,535. The stock’s 50-day moving average price is $9.88 and its 200-day moving average price is $9.18. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -5.70 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The firm had revenue of $10.89 million during the quarter, compared to analysts’ expectations of $12.37 million. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RXRX. TD Cowen began coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a “market perform” rating on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Finally, KeyCorp lifted their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $12.75.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.